An Open-Label, Multi-Center, Follow up Study to Protocol 101/2 - Continued Treatment by Intravenously Administered IPL344 to Amyotrophic Lateral Sclerosis (ALS) Patients
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs IPL-344 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Immunity Pharma
- 08 Jan 2025 Planned End Date changed from 1 Feb 2026 to 1 Feb 2027.
- 08 Jan 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
- 03 Dec 2023 Planned End Date changed from 1 Dec 2022 to 1 Feb 2026.